Cochrane Review Finds Hyped Alzheimer's Drugs Lack Clinical Benefit for Patients
A major review conducted by the Cochrane organization, widely regarded as the gold standard for evidence analysis, has concluded that recently approved anti-amyloid drugs for Alzheimer's disease do not provide meaningful clinical benefits to patients. Published on April 16, 2026, the study analyzed data from 17 clinical trials involving over 20,000 individuals with mild cognitive impairment or early dementia. While the drugs, specifically lecanemab and donanemab, successfully removed amyloid plaques from the brain, researchers found that this biological change did not translate into significant improvements in patients' daily lives or disease progression. Lead author Francesco Nonino emphasized that the statistical differences observed were not clinically meaningful. These findings challenge the long-held hypothesis that eliminating amyloids directly benefits patients and raise serious concerns regarding the high costs and severe side effects, such as brain swelling and bleeding, associated with these treatments. Consequently, state-run health services in the United Kingdom and France have refused to cover these medications, despite their approval in the United States and European Union. The review suggests a need to reconsider current treatment strategies for Alzheimer's disease.
Wire timeline
Cochrane Review Finds Hyped Alzheimer's Drugs Lack Clinical Benefit for Patients
A major review conducted by the Cochrane organization, widely regarded as the gold standard for evidence analysis, has concluded that recently approved anti-amyloid drugs for Alzheimer's disease do not provide meaningful clinical benefits to patients. Published on April 16, 2026, the study analyzed data from 17 clinical trials involving over 20,000 individuals with mild cognitive impairment or early dementia. While the drugs, specifically lecanemab and donanemab, successfully removed amyloid plaques from the brain, researchers found that this biological change did not translate into significant improvements in patients' daily lives or disease progression. Lead author Francesco Nonino emphasized that the statistical differences observed were not clinically meaningful. These findings challenge the long-held hypothesis that eliminating amyloids directly benefits patients and raise serious concerns regarding the high costs and severe side effects, such as brain swelling and bleeding, associated with these treatments. Consequently, state-run health services in the United Kingdom and France have refused to cover these medications, despite their approval in the United States and European Union. The review suggests a need to reconsider current treatment strategies for Alzheimer's disease.
hurriyetdailynews